rxstat › Classes › Antiepileptics

Antiepileptics: shortage status in Canada

11 of the 15 antiepileptics rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Partial shortageBrivaracetam1 of 8 reported products affected · est. return Apr 3, 2026 Partial shortageCarbamazepine2 of 20 reported products affected · est. return Jun 26, 2026 Partial shortageClonazepam5 of 21 reported products affected Partial shortageLacosamide6 of 34 reported products affected · est. return Aug 10, 2026 Partial shortageLevetiracetam13 of 48 reported products affected · est. return Sep 11, 2026 Partial shortageOxcarbazepine3 of 8 reported products affected · est. return Dec 30, 2022 Partial shortagePerampanel1 of 8 reported products affected · est. return Jul 3, 2026 Partial shortagePhenytoin1 of 6 reported products affected · est. return Sep 1, 2026 Partial shortageStiripentol1 of 1 reported products affected Partial shortageTopiramate7 of 38 reported products affected · est. return Jul 7, 2026 Partial shortageValproic Acid3 of 24 reported products affected · est. return Dec 30, 2026 Shortage anticipatedEslicarbazepine0 of 4 reported products affected No current shortageLamotrigine No current shortagePhenytoin No current shortageVigabatrin

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.